The US Food and Drug Administration (FDA) has approved Abbott’s next-generation Xience Prime everolimus-eluting coronary stent system, used to treat coronary artery disease.

The Xience Prime uses cobalt chromium technology and features a ‘peak-to-valley’ design that gives the stent longitudinal strength and stability.

The stent uses a drug and biocompatible polymer similar to that of the Xience V everolimus-eluting coronary stent system.

The approval is backed by results from a prospective, open-label Spirit Prime clinical trial, which reported the Xience Prime met its primary endpoint, with low rates of target lesion failure after one year.

Xience Prime is available in the US, Europe, the Middle East and most of Asia.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.